CSL Limited of Australia will pay $102 million to buy the remaining 20% in a China plasma company, Wuhan Zhong Yuan Rui De Biological Products (RuiDe). One year ago, CSL acquired an 80% RuiDe stake from China’s Humanwell Healthcare Group for $352 million. The companies had a previous relationship: CSL had been supplying RuiDe with albumin for China. With the purchase, CSL became a full-fledged participant in China’s plasma collection and products market.
Source: China Biotoday
